| Medical and Health Sciences | Lifetime | 490 | PL 2 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 12 | PL 1 | 100.00 |
| Biological Sciences | 2021-2025 | 627 | PL 2 | 99.35 |
| Economics and Finance | 2021-2025 | 951 | PL 9 | 96.11 |
| Surgery | Lifetime | 91 | PL 1 | 99.92 |
| Cardiology and Cardiovascular Medicine | Lifetime | 381 | PL 5 | 99.52 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 427 | PL 1 | 98.71 |
| Cancer Research | Lifetime | 522 | PL 2 | 96.73 |
| Nephrology | Lifetime | 574 | PL 3 | 93.37 |
| Biotechnology | Lifetime | 610 | PL 8 | 88.62 |
| Surgery | 2021-2025 | 1 | PL 1 | 99.99 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 100 | PL 3 | 99.52 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 96 | PL 2 | 98.65 |
| Epidemiology | 2021-2025 | 266 | PL 1 | 97.87 |
| Cancer Research | 2021-2025 | 66 | PL 1 | 96.96 |
| Medical Physiology | 2021-2025 | 278 | PL 2 | 96.26 |
| Econometrics and Quantitative Economics | 2021-2025 | 659 | PL 9 | 96.00 |
| Biotechnology | 2021-2025 | 78 | PL 4 | 91.76 |
| Infectious Diseases | 2021-2025 | 403 | PL 1 | 92.02 |
| Clinical Neurology | 2021-2025 | 365 | PL 1 | 88.53 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 927 | PL 4 | 87.23 |
| Nutrition and Dietetics | 2021-2025 | 356 | PL 7 | 84.41 |
| Immunology | 2021-2025 | 625 | PL 4 | 81.60 |
| Lipoproteins and Cardiovascular Health | Lifetime | 17 | PL 1 | 99.86 |
| Cancer, Lipids, and Metabolism | Lifetime | 35 | PL 1 | 99.79 |
| COVID-19 Clinical Research Studies | Lifetime | 147 | PL 1 | 99.19 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 148 | PL 1 | 99.49 |
| Pharmaceutical Economics and Policy | Lifetime | 30 | PL 1 | 99.12 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 80 | PL 1 | 99.62 |
| Long-Term Effects of COVID-19 | Lifetime | 146 | PL 1 | 98.49 |
| Microbial Metabolism and Applications | Lifetime | 56 | PL 1 | 98.58 |
| Blood Pressure and Hypertension Studies | Lifetime | 277 | PL 3 | 99.06 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 313 | PL 1 | 98.54 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 911 | PL 3 | 98.33 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 255 | PL 2 | 98.10 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 799 | PL 4 | 98.16 |
| Heart Failure Treatment and Management | Lifetime | 540 | PL 4 | 98.02 |
| Cardiovascular Health and Disease Prevention | Lifetime | 502 | PL 3 | 97.70 |
| Computational Drug Discovery Methods | Lifetime | 837 | PL 4 | 96.85 |
| Curcumin's Biomedical Applications | Lifetime | 123 | PL 2 | 96.22 |
| Nutritional Studies and Diet | Lifetime | 746 | PL 1 | 97.65 |
| Cardiovascular Disease and Adiposity | Lifetime | 896 | PL 2 | 95.88 |
| Chronic Kidney Disease and Diabetes | Lifetime | 597 | PL 4 | 96.86 |
| Diet, Metabolism, and Disease | Lifetime | 948 | PL 7 | 95.99 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 824 | PL 7 | 96.64 |
| Lipid metabolism and disorders | Lifetime | 448 | PL 1 | 95.40 |
| Cardiac Health and Mental Health | Lifetime | 746 | PL 2 | 95.58 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 378 | PL 2 | 93.57 |
| Cardiovascular Health and Risk Factors | Lifetime | 513 | PL 1 | 93.93 |
| Cholesterol and Lipid Metabolism | Lifetime | 746 | PL 2 | 94.13 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 100 | PL 3 | 93.19 |
| Telomeres, Telomerase, and Senescence | Lifetime | 478 | PL 5 | 93.04 |
| Sodium Intake and Health | Lifetime | 416 | PL 6 | 94.09 |
| Nutrition, Genetics, and Disease | Lifetime | 907 | PL 7 | 91.70 |
| GDF15 and Related Biomarkers | Lifetime | 279 | PL 3 | 87.70 |
| Coenzyme Q10 studies and effects | Lifetime | 349 | PL 3 | 88.27 |
| Vitamin K Research Studies | Lifetime | 1,000 | PL 8 | 80.59 |
| Cynara cardunculus studies | Lifetime | 346 | PL 15 | 75.18 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 1 | PL 1 | 99.98 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 5 | PL 1 | 99.81 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 5 | PL 1 | 99.89 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 4 | PL 1 | 99.86 |
| Microbial Metabolism and Applications | 2021-2025 | 6 | PL 1 | 98.13 |
| COVID-19 Clinical Research Studies | 2021-2025 | 209 | PL 1 | 98.91 |
| Long-Term Effects of COVID-19 | 2021-2025 | 140 | PL 1 | 98.23 |
| Lipid metabolism and disorders | 2021-2025 | 15 | PL 1 | 97.89 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 42 | PL 2 | 95.36 |
| Pharmaceutical Economics and Policy | 2021-2025 | 28 | PL 1 | 97.22 |
| Cardiac Health and Mental Health | 2021-2025 | 61 | PL 1 | 97.01 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 50 | PL 1 | 96.62 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 69 | PL 1 | 95.53 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 137 | PL 1 | 94.18 |
| Nutrition, Genetics, and Disease | 2021-2025 | 71 | PL 2 | 92.55 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 269 | PL 1 | 96.17 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 994 | PL 4 | 95.79 |
| Curcumin's Biomedical Applications | 2021-2025 | 58 | PL 2 | 91.95 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 143 | PL 1 | 93.45 |
| Computational Drug Discovery Methods | 2021-2025 | 606 | PL 4 | 93.67 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 294 | PL 3 | 91.09 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 383 | PL 8 | 91.86 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 650 | PL 6 | 91.19 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 325 | PL 1 | 87.11 |
| Inflammasome and immune disorders | 2021-2025 | 461 | PL 1 | 88.31 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 113 | PL 2 | 84.84 |
| Cardiovascular Issues in Pregnancy | 2021-2025 | 438 | PL 3 | 84.52 |
| HIV-related health complications and treatments | 2021-2025 | 543 | PL 3 | 84.13 |
| Folate and B Vitamins Research | 2021-2025 | 471 | PL 11 | 77.41 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 644 | PL 3 | 70.51 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 320 | PL 5 | 67.90 |
| Biochemical effects in animals | 2021-2025 | 883 | PL 16 | 68.94 |
| Sodium Intake and Health | 2021-2025 | 677 | PL 13 | 64.53 |
| Ginkgo biloba and Cashew Applications | 2021-2025 | 324 | PL 5 | 60.25 |
| Vitamin C and Antioxidants Research | 2021-2025 | 836 | PL 23 | 55.25 |